{"entity":{"id":"nct06598371","kind":"trial","name":"A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of KSQ-004EX run by M.D. Anderson Cancer Center, now recruiting.","summary":"A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06598371 by M.D. Anderson Cancer Center, with 141 participants planned, started 2024-11-21, primary completion expected 2039-08-01. Conditions recorded: Select Advanced Solid Tumors. Interventions recorded: Cyclophosphamide, Fludarabine, KSQ-004EX, Interleukin-2.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT06598371","url":"https://clinicaltrials.gov/study/NCT06598371"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["ksq-004ex"],"companies":["ksq-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06598371","phase":"1/2","setting":"A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors","sponsor":"M.D. Anderson Cancer Center","enrolled":141,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06598371/","neighbours":{"drug":[{"id":"ksq-004ex","kind":"drug","name":"KSQ-004EX","route":"/drugs/ksq-004ex/"}],"company":[{"id":"ksq-therapeutics","kind":"company","name":"KSQ Therapeutics","route":"/companies/ksq-therapeutics/"}]}}